同步放化疗治疗晚期非小细胞肺癌的临床效果
|
摘要
目的探讨同步放化疗治疗晩期非小细胞肺癌的临床效果。方法选取我院肿瘤科2016年1月～2018年1月收治的100例晚期非小细胞肺癌患者作为研究对象,以远程随机化法分为对照组和实验组,各50例。对照组接受序贯放化疗,实验组接受同步放化疗,比较两组的治疗效果、不良反应发生率以及生活质量。结果实验组的治疗总有效率为66.00%,明显高于对照组的42.00%,差异有统计学意义(P<0.05)。实验组的白细胞下降、放射性食管炎以及放射性肺损伤等不良反应发生率以及严重程度与对照组比较,差异无统计学意义(P>0.05)。实验组治疗后的生活质量评分均明显高于对照组,差异有统计学意义(P<0.05)。结论晚期非小细胞肺癌患者接受同步放化疗具有较好的治疗效果,对提高其生活质量、延长寿命有着积极的意义。
Objective To investigate the clinical effects of concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer. Methods A total of 100 patients with advanced non-small cell lung cancer from January2016 to January 2018 in the department of oncology in our hospital were selected as research subjects. According to the method of remote randomization, all the patients were divided into the control group and the experimental group, 50 cases in each group. The control group was given sequential chemotherapy and radiotherapy. The experimental group was given concurrent chemoradiotherapy. The therapeutic efficacy, the incidence of adverse reactions and quality of life of patients with advanced non-small cell lung cancer were compared between the two groups. Results The total effective rate of treatment in the patients with advanced non-small cell lung cancer in the experimental group was 66.00%,which was significantly higher than 42.00% in the control group, the difference was statistically significant(P<0.05).The incidence rate and severity of adverse reactions such as leukopenia, radiation esophagitis, and radiation-induced lung injury in the experimental group were compared with the control group, and the differences were not statistically significant(P>0.05). The quality of life scores in the experimental group after treatment were significantly higher than those in the control group, and the difference was statistically significant(P<0.05). Conclusion Patients with advanced non-small cell lung cancer receive concurrent chemoradiotherapy has a good therapeutic effect. It has a positive significance for improving the quality of life and extending life expectancy.
Objective To investigate the clinical effects of concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer. Methods A total of 100 patients with advanced non-small cell lung cancer from January2016 to January 2018 in the department of oncology in our hospital were selected as research subjects. According to the method of remote randomization, all the patients were divided into the control group and the experimental group, 50 cases in each group. The control group was given sequential chemotherapy and radiotherapy. The experimental group was given concurrent chemoradiotherapy. The therapeutic efficacy, the incidence of adverse reactions and quality of life of patients with advanced non-small cell lung cancer were compared between the two groups. Results The total effective rate of treatment in the patients with advanced non-small cell lung cancer in the experimental group was 66.00%,which was significantly higher than 42.00% in the control group, the difference was statistically significant(P<0.05).The incidence rate and severity of adverse reactions such as leukopenia, radiation esophagitis, and radiation-induced lung injury in the experimental group were compared with the control group, and the differences were not statistically significant(P>0.05). The quality of life scores in the experimental group after treatment were significantly higher than those in the control group, and the difference was statistically significant(P<0.05). Conclusion Patients with advanced non-small cell lung cancer receive concurrent chemoradiotherapy has a good therapeutic effect. It has a positive significance for improving the quality of life and extending life expectancy.
引文
[1]李伟,张海燕,宋霆婷,等.肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的疗效及安全性[J].疑难病杂志,2015,14(5):480-482,486.
[2]邓立勇.非小细胞肺癌脑转移铂类化疗同步放疗或序贯放化疗的疗效分析[J].实用癌症杂志,2016,31(12):2000-2003.
[3]李继泉,崔李平.Ⅲ期非小细胞肺癌患者肺癌根治术后同步放化疗效果观察[J].山东医药,2015,55(42):56-58.
[4]闫瑞敏,杨昊,郁志龙,等.肺癌同步化疗与序贯化疗联合调强放疗的疗效比较[J].内蒙古医科大学学报,2015,57(1):74-76.
[5]陈宓,贾霖,韩建军,等.肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的疗效及安全性研究[J].现代生物医学进展,2016,16(35):6913-6915.
[6]王利琴,谢淑萍,沈佳琴,等.肺癌患者55例放疗同步化疗期间营养状况分析[J].中国基层医药,2016,23(22):3373-3377.
[7]柯春林,罗荣刚,林剑波,等.多西他赛顺铂联合同步放疗治疗Ⅲ期非小细胞肺癌的临床疗效及安全性[J].中国临床药理学杂志,2015,31(21):2102-2104.
[8]谭佳安.同步放化疗联合扶正肺癌方治疗局部晚期非小细胞肺癌的临床研究[D].武汉:湖北中医药大学,2016.
[9]翟小明,顾科,俞家华,等.放化疗联合胸腔镜手术治疗ⅢA N2期非小细胞肺癌的临床效果[J].实用医学杂志,2014,43(19):3099-3101.
[10]骆红蕾,喻晓娟,李进,等.125I粒子植入联合化疗治疗同期放化疗后局部复发的Ⅲ期非小细胞肺癌[J].中华核医学与分子影像杂志,2013,33(3):195-198.
[11]马红莲,惠周光,赵路军,等.不可切除Ⅲ期NSCLC持续静脉泵注恩度联合同期放化疗前瞻性多中心Ⅱ期临床试验初步结果[J].中华放射肿瘤学杂志,2016,25(2):114-119.
[12]田秀明,王玉祥,邱嵘,等.70岁及以上老年人Ⅲ期非小细胞肺癌三维适形放疗的预后因素[J].中华老年医学杂志,2017,36(9):970-974.
[13]王谨,包勇,庄婷婷,等.非小细胞肺癌同期放化疗后重度急性放射性肺炎的预测模型研究[J].中华放射肿瘤学杂志,2013,22(6):455-459.
[14]周熙平.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].中国急救医学,2015,35(z2):134-135.
[15]别志欣,郭军.同期放化疗与序贯放化疗治疗诱导化疗无效局限期NSCLC患者的疗效比较[J].医学临床研究,2017,34(4):693-695.
[2]邓立勇.非小细胞肺癌脑转移铂类化疗同步放疗或序贯放化疗的疗效分析[J].实用癌症杂志,2016,31(12):2000-2003.
[3]李继泉,崔李平.Ⅲ期非小细胞肺癌患者肺癌根治术后同步放化疗效果观察[J].山东医药,2015,55(42):56-58.
[4]闫瑞敏,杨昊,郁志龙,等.肺癌同步化疗与序贯化疗联合调强放疗的疗效比较[J].内蒙古医科大学学报,2015,57(1):74-76.
[5]陈宓,贾霖,韩建军,等.肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的疗效及安全性研究[J].现代生物医学进展,2016,16(35):6913-6915.
[6]王利琴,谢淑萍,沈佳琴,等.肺癌患者55例放疗同步化疗期间营养状况分析[J].中国基层医药,2016,23(22):3373-3377.
[7]柯春林,罗荣刚,林剑波,等.多西他赛顺铂联合同步放疗治疗Ⅲ期非小细胞肺癌的临床疗效及安全性[J].中国临床药理学杂志,2015,31(21):2102-2104.
[8]谭佳安.同步放化疗联合扶正肺癌方治疗局部晚期非小细胞肺癌的临床研究[D].武汉:湖北中医药大学,2016.
[9]翟小明,顾科,俞家华,等.放化疗联合胸腔镜手术治疗ⅢA N2期非小细胞肺癌的临床效果[J].实用医学杂志,2014,43(19):3099-3101.
[10]骆红蕾,喻晓娟,李进,等.125I粒子植入联合化疗治疗同期放化疗后局部复发的Ⅲ期非小细胞肺癌[J].中华核医学与分子影像杂志,2013,33(3):195-198.
[11]马红莲,惠周光,赵路军,等.不可切除Ⅲ期NSCLC持续静脉泵注恩度联合同期放化疗前瞻性多中心Ⅱ期临床试验初步结果[J].中华放射肿瘤学杂志,2016,25(2):114-119.
[12]田秀明,王玉祥,邱嵘,等.70岁及以上老年人Ⅲ期非小细胞肺癌三维适形放疗的预后因素[J].中华老年医学杂志,2017,36(9):970-974.
[13]王谨,包勇,庄婷婷,等.非小细胞肺癌同期放化疗后重度急性放射性肺炎的预测模型研究[J].中华放射肿瘤学杂志,2013,22(6):455-459.
[14]周熙平.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].中国急救医学,2015,35(z2):134-135.
[15]别志欣,郭军.同期放化疗与序贯放化疗治疗诱导化疗无效局限期NSCLC患者的疗效比较[J].医学临床研究,2017,34(4):693-695.